Author

Lokesh Kumar

Translational Health Science and Technology InstitutePrimary ORCID profile (0009-0006-7506-9100 · 1 paper)Unclaimed ORCID profile · follow to get notified of new preprints

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

Lokesh KumariD1 paper · Washington University in St. Louis

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1 Organism:mouse· 1

Frequent Co-Authors

Akash BagheliD· 1 shared Anita KumariiD· 1 shared Kritida Dhar· 1 shared Phulwanti Kumari SharmaiD· 1 shared Pradipta JanaiD· 1 shared Rajni YadaviD· 1 shared Ruby Bansal· 1 shared Ruchi Tandon· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperPharmacology & Toxicology

Akash BaghelORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Gut microbiota-derived indole-3 acetic acid mitigates key hallmarks of metabolic dysfunction-associated steatotic liver disease (MASLD) in an NLRP3-dependent manner in in vitro and diet-induced mouse models

Phulwanti Kumari Sharma, Lokesh Kumar, Akash Baghel, Pradipta Jana, Kritida Dhar, Ruby Bansal, Yamini Goswami, Anita Kumari, Rajni Yadav, S. Shalimar, Shailendra Asthana, Ruchi Tandon

This study identifies indole-3 acetic acid (I3A) as an NLRP3 inflammasome inhibitor that mitigates MASLD hallmarks in vitro and in diet-induced mouse models.

bioRxiv · Jan 27, 2026 · PreprintPharmacology & Toxicology